CD23: Difference between revisions
From haematologyetc.co.uk
(Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :<span style="color:navy">'''Summary'''</span> :xxxx </div> <span style="color:navy">'''Normal expression and function'''</span> xxxxx <span style="color:navy">'''Diagnostic role'''</span> *xxxxx <span style="color:navy">'''Other relevant information:'''</span> xxxxx ---- <span style="color:navy">'''''SUMMARY TABLES'''''</span> <span style="font-...") |
No edit summary |
||
Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
: | :CD23 is a broadly expressed molecule whose impotance lies in its value in distinguishing between CLL (consistent expression) and MCL (infrequent expression). | ||
:However, CD23 is not a CLL-specific marker, and is also expressed on other haematological and lymphoma cell types. | |||
Line 14: | Line 15: | ||
<span style="color:navy">'''Normal expression and function'''</span> | <span style="color:navy">'''Normal expression and function'''</span> | ||
CD23 is a low-affinity receptor for IgE that is involved in antigen capture and presentation. It affects B-cell growth and differentiation and the activation of monocytes. It is expressed on activated B-cells, but also platelets eosinophils activated macrophages and follicular dendritic cells. | |||
<span style="color:navy">'''Additional Information'''</span> | |||
When CD23 is expressed by MCL the cases may have a more indolent course and an improved outcome. | |||
<span style="color:navy">'''Diagnostic role'''</span> | <span style="color:navy">'''Diagnostic role'''</span> | ||
* | *CD23 is most frequently used to distinguish between CLL and MCL but this difference is not absolute: CD23 is expressed by the vast majority (90% of typical CLL patients), and is generally absent in MCL although it is detected in around 10% of cases where its expression may be bright. | ||
*CD23 may also be expressed by other B-lymphoproliferative disorders although at lower frequency:including lymphoplasmacytic lymphoma, marginal zone lymphoma or follicular lymphoma. | |||
Revision as of 22:21, 12 May 2023
- Summary
- CD23 is a broadly expressed molecule whose impotance lies in its value in distinguishing between CLL (consistent expression) and MCL (infrequent expression).
- However, CD23 is not a CLL-specific marker, and is also expressed on other haematological and lymphoma cell types.
Normal expression and function
CD23 is a low-affinity receptor for IgE that is involved in antigen capture and presentation. It affects B-cell growth and differentiation and the activation of monocytes. It is expressed on activated B-cells, but also platelets eosinophils activated macrophages and follicular dendritic cells.
Additional Information
When CD23 is expressed by MCL the cases may have a more indolent course and an improved outcome.
Diagnostic role
- CD23 is most frequently used to distinguish between CLL and MCL but this difference is not absolute: CD23 is expressed by the vast majority (90% of typical CLL patients), and is generally absent in MCL although it is detected in around 10% of cases where its expression may be bright.
- CD23 may also be expressed by other B-lymphoproliferative disorders although at lower frequency:including lymphoplasmacytic lymphoma, marginal zone lymphoma or follicular lymphoma.
Other relevant information:
xxxxx
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
Expression in primitive cell types | |||||||
---|---|---|---|---|---|---|---|
AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
Expression in mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
Expression in mature T cell neoplasms* | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx